WallStSmart

Quipt Home Medical Corp (QIPT)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 1937% more annual revenue ($5.40B vs $264.97M). RMD leads profitability with a 27.5% profit margin vs -4.0%. RMD earns a higher WallStSmart Score of 70/100 (B).

QIPT

Hold

40

out of 100

Grade: D

Growth: 7.3Profit: 2.5Value: 5.0Quality: 5.0

RMD

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 8.7Quality: 8.3
Piotroski: 6/9Altman Z: 4.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for QIPT.

RMDUndervalued (+14.4%)

Margin of Safety

+14.4%

Fair Value

$303.30

Current Price

$226.31

$76.99 discount

UndervaluedFair: $303.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

QIPT2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
32.0%10/10

Revenue surging 32.0% year-over-year

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.7%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

Areas to Watch

QIPT4 concerns · Avg: 2.5/10
Market CapQuality
$162.30M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
1.5%3/10

Operating margin of 1.5%

Return on EquityProfitability
-9.3%2/10

ROE of -9.3% — below average capital efficiency

EPS GrowthGrowth
-97.7%2/10

Earnings declined 97.7%

RMD0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : QIPT

The strongest argument for QIPT centers on Revenue Growth, Price/Book. Revenue growth of 32.0% demonstrates continued momentum.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.

Bear Case : QIPT

The primary concerns for QIPT are Market Cap, Operating Margin, Return on Equity.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Key Dynamics to Monitor

QIPT profiles as a hypergrowth stock while RMD is a mature play — different risk/reward profiles.

RMD carries more volatility with a beta of 0.89 — expect wider price swings.

QIPT is growing revenue faster at 32.0% — sustainability is the question.

RMD generates stronger free cash flow (311M), providing more financial flexibility.

Bottom Line

RMD scores higher overall (70/100 vs 40/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Quipt Home Medical Corp

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Quipt Home Medical Corp. The company is headquartered in Wilder, Kentucky.

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?